Browsing by Author "Pehlivan, Y."

Now showing 1 - 12 of 12

A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting from Turkbio registry
(Bmj Publishing Group, 2021-06-01) Yazici, A.; Isik, O. Ozdemir; Koca, S. S.; Senel, S.; Inanc, N.; Akar, S.; Yilmaz, S.; Gunduz, O. Soysal; Cefle, A.; Onen, F.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Pehlivan, Y.; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-2167-4509; 0000-0002-3835-466X; 0000-0002-3734-1242; 0000-0002-6341-2622; JBI-6627-2023; AAT-3636-2020; HTP-6798-2023; AAA-8970-2021; HJY-2666-2023; JDV-5142-2023
Are there any differences between adult-onset rheumatoid arthritis patients and late-onset rheumatoid arthritis patients in terms of use of biological drugs and drug retention rate? Results from the Turkbio registry
(Bmj Publishing Group, 2020-06-01) Yazici, A.; Cefle, A.; Can, G.; Senel, S.; Koca, S. S.; Inanc, N.; Goker, B.; Yilmaz, S.; Akar, S.; Soysal, O.; Ozturk, M. A.; Sari, I.; Direskeneli, H.; Onen, F.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Pehlivan, Y.; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; AAG-8227-2021
Biosimilar infliximab experience in spondyloartritis patients: Treasure real life results
(Bmj Publishing Group, 2020-06-01) Bilge, N. S. Yasar; Kasifoglu, T.; Kiraz, S.; Ertenli, A. I.; Bes, C.; Emmungil, H.; Cinar, M.; Akar, S.; Gercik, O.; Ersozlu, D.; Kimyon, G.; Mercan, R.; Kilic, L.; Kalyoncu, U.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Seniz, B. N.; Yagiz, B.; YAĞIZ, BURCU; Karadag, O.; Pehlivan, Y.; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-3443-3117; AAV-7175-2021; JQW-5031-2023; AAD-5448-2019; AAG-8227-2021
Disease duration and hla-b27 positivity alter longterm retention rate of certolizumab pegol in patients with psoriatic arthritis
(Bmj Publishing Group, 2021-06-01) Koca, S. S.; Pehlivan, Y.; Akar, S.; Senel, S.; Karadeniz, H.; Sosyal, O.; Yazici, A.; Yilmaz, S.; Sagir, R. Piskin; Inanc, N.; Karatas, A.; Cetin, G. Yildirim; Onen, F.; Pehlivan, Y.; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; 0000-0002-3734-1242; 0000-0003-4665-3421; 0000-0003-2167-4509; 0000-0002-6725-4182; 0000-0001-9680-7535; 0000-0002-6341-2622; AAT-3636-2020; AAA-8970-2021; E-7046-2016; HTP-6798-2023; HJY-2666-2023
Do comorbidities decrease the first tnf-inhibitor retention and treatment response in axial spondyloarthritis patients? Data from Turkbio
(BMJ Publishing Group, 2020-06-01) Erez, Y.; Karakaş, A.; Kocaer, S. B.; İnel, T. Yüce; Gülle, S.; Avşar, A. Köken; Uslu, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Şenel, S.; Akar, S.; Koca, S. S.; Tufan, A.; Yazıcı, A.; Yılmaz, S.; İnanç, N.; Solmaz, D.; Akkoç, N.; Önen, F.; TURKBIO Study Group; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021; JHC-5173-2023
Do comorbidities impact persistence of first tumor necrosis factor inhibitor treatment in rheumatoid arthritis? Data from Turkbio
(BMJ Publishing Group, 2020-06-01) İnel, T. Yüce; Kocaer, S. B.; Erez, Y.; Gülle, S.; Karakaş, A.; Avşar, A. Köken; Uslu, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Akar, S.; Göker, B.; Çetin, G. Yıldırım; Haznedaroğlu, S.; Yavuz, S.; Pırıldar, T.; Direskeneli, H.; Akkoç, N.; Önen, F.; Turkbio Registry Group; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; AAG-8227-2021; JHC-5173-2023
Do peripheral and extra musculoskeletal manifestations have an impact on biologic dmard prescribing patterns in axial spondyloarthritis: The results of treasure experience
(Bmj Publishing Group, 2021-06-01) Ediboglu, E. Durak; Solmaz, D.; Karadag, O.; Cinar, M.; Ertenli, A. I.; Ersozlu, D.; Kucuksahin, O.; Ates, A.; Kiraz, S.; Tekgoz, E.; Emmungil, H.; Gonullu, E.; Kabadayi, G.; Kasifoglu, T.; Mercan, R.; Kimyon, G.; Colak, S.; Bes, C.; Bilge, N. S. Yasar; Yazisiz, V.; Koca, S. S.; Atagunduz, P.; Kanitez, N. A.; Kalyoncu, U.; Akar, S.; Pehlivan, Y.; Coskun, B. N.; COŞKUN, NEJDET; Yagiz, B.; YAĞIZ, BURCU; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Kimya Bölümü.; 0000-0002-9035-689X; 0000-0003-1372-1555; 0000-0002-0866-1503; 0000-0001-5184-4404; 0000-0002-6990-4206; 0000-0003-2076-3403; 0000-0003-1185-5816; 0000-0002-3734-1242; HJY-2666-2023; JQW-5031-2023; HJI-6996-2023; AAG-7155-2021; GZA-3287-2022; B-1448-2016; AFO-6929-2022; AAZ-5845-2021; AAD-5448-2019; AAK-7851-2021; W-7332-2019
Infliximab therapy in behcet's uveitis
(Masson Editeur, 2022-10-20) Alizadegan, F.; Yalçınbayır, O.; Gündüz, G. Uçan; Pehlivan, Y.; PEHLİVAN, YAVUZ; YALÇINBAYIR, ÖZGÜR; 0000-0002-7311-5277; 0000-0002-5458-1686; IYJ-9408-2023; AAH-6661-2021
Purpose. - To evaluate the efficacy of infliximab (IFX) therapy in patients with Behc , et's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).Materials and methods. - This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic char-acteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Results. - Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 +/- 25.9 months. The mean frequency of recurrences during the IMT was 1.47 +/- 0.78 (attacks/year), decreasing to 0.31 +/- 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases.Conclusion. - IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.
Long-term survival of the first biologic treatment in psoriatic arthritis and the effect of the selected treatment on drug survival; Turkbio registry
(BMJ, 2020-06-01) Kocaer, S. B.; İnel, T. Yüce; Erez, Y.; Avşar, A. Köken; Uslu, S.; Karakaş, A.; Gülle, S.; Can, G.; Sarı, I.; Birlik, M.; Dalkılıç, E.; Pehlivan, Y.; Akar, S.; Cefle, A.; Öztürk, M. A.; Yolbaş, S.; Yılmaz, N.; Erten, S.; Akkoç, N.; Önen, F.; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; JHC-5173-2023; AAG-8227-2021
Paraneoplastic arthritis: A multi-centered experience
(Bmj Publishing Group, 2013-06-01) Kısacık, B.; Onat, A. M.; Kaşifoğlu, T.; Pehlivan, Y.; Pamuk, O. N.; Dönmez, S.; Bilge, S. Y.; Yılmaz, S.; Erdern, H.; Mercan, R.; Öztürk, M. A.; Bes, C.; Soy, M.; Erten, S.; Çobankara, V.; Şenel, S.; Öner, F. A.; Direskeneli, H.; Yilmaz, S.; Kul, S.; Çetin, G. Y.; Sayarlioğlu, M.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.
Treatment satisfaction with tumour necrosis factor-alpha inhibitors (anti-tnf) in ankylosing spondylitis
(Bmj Publishing Group, 2015-06-01) Balci, M. A.; Durmus, Y.; Donmez, S.; Öksüzi, M. F.; Tufan, A. N.; Sahin, A. B.; Göçken, A.; Dalkılıç, E.; DALKILIÇ, HÜSEYİN EDİZ; Pamuk, O. N.; Pehlivan, Y.; PEHLİVAN, YAVUZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-1465-7153; 0000-0002-7846-0870; AAG-8227-2021; AAM-4927-2020; B-4948-2017
Work producivity in rheumatoid arthritis: Analysis from multicenter Turkish study
(Bmj Publishing Group, 2015-06-01) Pamuk, O. N.; Çetin, P.; Solmaz, D.; Ertenli, I.; Akar, S.; Karaaslan, Y.; Sarı, R. A.; Aksu, K.; Atagündüz, P.; Şentürk, T.; Cefle, A.; Çobankara, V.; Kobak, S.; Koca, S. S.; Pehlivan, Y.; Tufan, A.; Akyol, L.; Gök, K.; Küçükşahin, O.; Dönmez, S.; Akkoç, N.; PEHLİVAN, YAVUZ; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; AAG-8227-2021